Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Purethal Birch Immunotherapy in Local Allergic Rhinitis
NCT03157505Phase 3Completed
- Sponsor
- Medical University of Silesia
- Start
- Jan 2014
- Primary completion
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) comparing Purethal Birch with Placebo (2 arms). Primary endpoint: Area Under the Curve of Symptoms Medication Score at 24 months. Started Jan 2014; status: completed.
02
Drugs
Purethal Birch
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT03157505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03157505.